ST GLIPTIN 3D 500 by Steris Healthcare: A Complete Product Guide

 ST GLIPTIN 3D 500 contains sitagliptin 100 mg, metformin hydrochloride 500 mg sustained release and pioglitazone 15 mg. This combination brings together three medicines that work through different mechanisms to help manage blood glucose levels in adults with type 2 diabetes mellitus.

Type 2 diabetes is a long-term condition in which the body does not use insulin effectively and may not produce enough insulin to maintain healthy blood glucose levels. Over time, persistently elevated blood sugar can increase the risk of complications affecting the eyes, kidneys, nerves, heart and blood vessels. Effective diabetes management usually involves appropriate medication, balanced nutrition, regular physical activity and monitoring as recommended by a healthcare professional.

Sitagliptin helps regulate glucose-dependent insulin release, metformin reduces glucose production by the liver and improves insulin sensitivity, while pioglitazone improves the body's response to insulin. Together, these medicines target different aspects of glucose regulation.

ST GLIPTIN 3D 500, marketed by Steris Healthcare Pvt. Ltd., should be used only when a qualified healthcare professional considers this combination suitable. The choice of treatment depends on blood glucose levels, kidney and liver function, other medical conditions and the patient's existing medicines.

This medicine is not intended for type 1 diabetes or the treatment of diabetic ketoacidosis. It should not be started, stopped or adjusted without medical guidance.

Why Is This Combination Important?

Managing type 2 diabetes may require more than one medicine because blood glucose is controlled through several interconnected processes. A combination containing sitagliptin, sustained-release metformin and pioglitazone targets different pathways involved in blood sugar regulation.

Sitagliptin supports the body's incretin hormone system, which helps regulate insulin release after meals. Metformin helps limit the amount of glucose released by the liver, while pioglitazone helps muscle and other tissues respond more effectively to insulin.

Using medicines with complementary mechanisms may help healthcare professionals develop an individualised diabetes treatment plan when a single medicine is insufficient. However, a three-medicine combination is not appropriate for everyone. Its suitability must be assessed against the patient's treatment history, current glucose control, kidney function, risk of fluid retention and other relevant factors.

Key Benefits of ST GLIPTIN 3D 500

The potential benefits of this prescription combination relate to its three complementary glucose-lowering mechanisms.

• Supports blood glucose management: The ingredients target different processes involved in maintaining blood sugar levels.

• Helps regulate glucose after meals: Sitagliptin supports glucose-dependent insulin secretion.

• Helps reduce excess liver glucose production: Metformin contributes to better glucose control.

• Improves insulin sensitivity: Pioglitazone helps the body respond more effectively to insulin.

• Combines three medicines in one treatment regimen: When prescribed appropriately, a combination product may simplify a patient's medication schedule.

Individual results vary. The medicine should be used alongside a personalised diabetes care plan, not as a replacement for healthy lifestyle habits or regular medical follow-up.

Side Effects of ST GLIPTIN 3D 500

Like other prescription medicines used for diabetes, ST GLIPTIN 3D 500 may cause side effects. The effects experienced can differ between individuals.

Possible side effects associated with its ingredients include:

• Nausea, diarrhoea, abdominal discomfort or other digestive symptoms.

• Headache or symptoms associated with changes in blood glucose.

• Swelling of the feet or ankles due to fluid retention.

• Weight gain, which may occur with pioglitazone.

• Low blood glucose, particularly when used with insulin or certain other diabetes medicines.

Metformin can rarely cause a serious condition called lactic acidosis, while sitagliptin has been associated with pancreatitis and serious hypersensitivity reactions.

If side effects persist or interfere with daily activities, contact your prescribing healthcare professional. Do not independently change the dose or discontinue treatment.

Serious Side Effects of ST GLIPTIN 3D 500

Certain symptoms require prompt medical assessment.

• Heart failure or fluid retention: New or worsening breathlessness, rapid weight gain or significant swelling of the legs may indicate fluid retention or worsening heart failure. Pioglitazone carries an important heart-failure warning.

• Pancreatitis: Severe, persistent abdominal pain, particularly when it spreads to the back and is accompanied by vomiting, needs urgent evaluation.

• Lactic acidosis: Unusual weakness, muscle pain, breathing difficulty, abdominal discomfort or marked drowsiness may indicate a rare but serious complication associated with metformin.

• Severe allergic reaction: Facial or throat swelling, breathing difficulty or a widespread severe rash requires emergency medical attention.

• Significant hypoglycaemia: Sweating, shaking, confusion, dizziness or loss of consciousness may indicate dangerously low blood glucose, especially when other glucose-lowering medicines are also used.

Seek urgent medical care if any serious symptoms occur.

Available Substitutes for ST GLIPTIN 3D 500

Alternative diabetes treatments may include other combinations of sitagliptin and metformin, medicines combining metformin with other glucose-lowering agents, or separate medicines prescribed according to an individual's needs.

However, a suitable substitute must be assessed carefully because ST GLIPTIN 3D 500 contains three ingredients, including pioglitazone. A product containing only sitagliptin and metformin would not provide the same composition.

Before switching, the prescriber should verify the active ingredients, strengths, sustained-release formulation, dosing schedule and clinical suitability. Do not substitute one diabetes medicine for another based on brand name or price alone.

Dosage Guidelines for ST GLIPTIN 3D 500

ST GLIPTIN 3D 500 should be taken only in the dose and frequency prescribed by a qualified healthcare professional. The appropriate regimen depends on the patient's current diabetes treatment, glucose control, kidney and liver function, tolerance and other medical conditions.

• Take the medicine according to the prescription and product instructions.

• Confirm whether the specific product should be taken with meals.

• Swallow sustained-release tablets as directed; do not crush or chew them unless the product instructions explicitly permit it.

• If you miss a dose, follow your prescription or ask your pharmacist for advice. Do not double the next dose.

• Continue recommended blood glucose monitoring and attend scheduled follow-up appointments.

Kidney function must be assessed before and during treatment because metformin and sitagliptin have important renal dosing considerations. The exact dose and schedule must be determined by the prescriber rather than inferred from the ingredient strengths alone.

Precautions and Warnings

Before starting ST GLIPTIN 3D 500, tell your doctor about your complete medical history and all medicines or supplements you take.

Kidney problems: Metformin and sitagliptin require particular attention to kidney function. Severe kidney impairment may make treatment unsuitable.

Heart disease: Pioglitazone can cause fluid retention and may worsen heart failure. Inform your doctor if you have heart failure, unexplained swelling or breathlessness.

Liver problems: Discuss any history of liver disease before treatment. Your clinician may recommend liver-function assessment.

Pregnancy and breastfeeding: Seek medical advice before using this combination during pregnancy, while planning pregnancy or during breastfeeding.

Alcohol consumption: Avoid excessive alcohol because it can increase the risk of metformin-associated lactic acidosis.

Other diabetes medicines: Insulin and certain other glucose-lowering medicines can increase the risk of hypoglycaemia when used in combination.

Surgery and contrast imaging: Tell your healthcare team that you take metformin before surgery or an imaging procedure involving iodinated contrast. Temporary interruption may be necessary in certain circumstances.

Bladder cancer history: Discuss any history of bladder cancer or unexplained blood in the urine with your doctor before using pioglitazone.

Do not use this medicine for type 1 diabetes or diabetic ketoacidosis. It is intended for appropriate patients with type 2 diabetes under professional supervision.

How to Use ST GLIPTIN 3D 500

Use ST GLIPTIN 3D 500 consistently according to your doctor's instructions. Follow the prescribed timing and meal instructions for the specific sustained-release formulation. Do not change the schedule, split tablets or crush them without checking the product directions.

Continue following your recommended meal plan, physical activity routine and blood glucose monitoring schedule. Keep a record of unusual readings or symptoms and share it with your healthcare professional during follow-up visits.

If you develop vomiting, dehydration, a severe infection or another significant acute illness, contact your healthcare professional because your diabetes medicines may need reassessment.

Mechanism of Action

ST GLIPTIN 3D 500 combines three glucose-lowering medicines with complementary mechanisms.

Sitagliptin 100 mg: Sitagliptin inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme, which breaks down incretin hormones. This increases the activity of these hormones, supporting glucose-dependent insulin release and helping reduce glucagon secretion when appropriate.

Metformin Hydrochloride 500 mg Sustained Release: Metformin primarily reduces glucose production in the liver and improves insulin sensitivity. The sustained-release formulation is designed to release the medicine gradually according to its formulation characteristics.

Pioglitazone 15 mg: Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ), influencing gene expression involved in glucose and lipid metabolism. This helps improve insulin sensitivity in body tissues.

Together, these ingredients address different mechanisms involved in blood glucose regulation. The combination's suitability depends on the individual's clinical condition and the balance of potential benefits and risks.

Conclusion

ST GLIPTIN 3D 500 combines sitagliptin 100 mg, metformin hydrochloride 500 mg sustained release and pioglitazone 15 mg to target different processes involved in blood glucose regulation in adults with type 2 diabetes.

The combination may be appropriate for selected patients when prescribed after considering their glucose control, kidney function, heart health and other individual risk factors. Regular monitoring, adherence to medical advice and appropriate lifestyle measures remain important parts of diabetes management.

Steris Healthcare Pvt. Ltd. is the supplied manufacturer/marketer information for this product. Verify the product label and current availability before purchasing, and use ST GLIPTIN 3D 500 only as directed by your healthcare professional.